PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

被引：0

作者：

Huaqiang Zhou

Jiaqing Liu

Yaxiong Zhang

Yan Huang

Jiayi Shen

Yunpeng Yang

Wenfeng Fang

Li Zhang

机构：

[1] Sun Yat-sen University Cancer Center,Department of Medical Oncology

[2] State Key Laboratory of Oncology in South China,Zhongshan School of Medicine

[3] Collaborative Innovation Center for Cancer Medicine,undefined

[4] Sun Yat-sen University,undefined

来源：

npj Precision Oncology | / 4卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.

引用

共 50 条

[1] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
Zhou, Huaqiang
Liu, Jiaqing
Zhang, Yaxiong
Huang, Yan
Shen, Jiayi
Yang, Yunpeng
Fang, Wenfeng
Zhang, Li
NPJ PRECISION ONCOLOGY, 2020, 4 (01)
[2] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
Liu, J.
Zhou, H.
Zhang, Y.
Huang, Y.
Yang, Y.
Fang, W.
Zhang, L.
ANNALS OF ONCOLOGY, 2019, 30
[3] Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer
Hallqvist, Andreas
Rohlin, Anna
Raghavan, Sukanya
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (06)
[4] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Hastings, K.
Yu, H. A.
Wei, W.
Sanchez-Vega, F.
DeVeaux, M.
Choi, J.
Rizvi, H.
Lisberg, A.
Truini, A.
Lydon, C. A.
Liu, Z.
Henick, B. S.
Wurtz, A.
Cai, G.
Plodkowski, A. J.
Long, N. M.
Halpenny, D. F.
Killam, J.
Oliva, I
Schultz, N.
Riely, G. J.
Arcila, M. E.
Ladanyi, M.
Zelterman, D.
Herbst, R. S.
Goldberg, S. B.
Awad, M. M.
Garon, E. B.
Gettinger, S.
Hellmann, M. D.
Politi, K.
ANNALS OF ONCOLOGY, 2019, 30 (08) : 1311 - 1320
[5] Role of the THE in immune checkpoint blockade resistance of non-small cell lung cancer
Dai, Yuening
Tian, Xueqi
Ye, Xuanting
Gong, Yabin
Xu, Ling
Jiao, Lijing
CANCER DRUG RESISTANCE, 2024, 7
[6] Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
Califano, Raffaele
Kerr, Keith
Morgan, Robert David
Lo Russo, Giuseppe
Garassino, Marina
Morgillo, Floriana
Rossi, Antonio
CURRENT ONCOLOGY REPORTS, 2016, 18 (09)
[7] Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
Raffaele Califano
Keith Kerr
Robert David Morgan
Giuseppe Lo Russo
Marina Garassino
Floriana Morgillo
Antonio Rossi
Current Oncology Reports, 2016, 18
[8] Association between lung microbiome and immune checkpoint blockade response in non-small cell lung cancer patients
Kim, Joon
Yong, Seung-Hyun
Kim, Eun Young
Oh, Chang-Myung
Lee, Sang Hoon
RESPIROLOGY, 2024, 29 : 52 - 52
[9] Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Ojlerta, Asa Kristina
Nebdal, Daniel
Lund-Iversen, Marius
Ellefsen, Renee Astrom
Brustugun, Odd Terje
Gran, Jon Michael
Halvorsen, Ann Rita
Helland, Aslaug
ACTA ONCOLOGICA, 2021, 60 (02) : 149 - 156
[10] A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
Jiang, Zedong
Zhou, Yao
Huang, Juan
FRONTIERS IN IMMUNOLOGY, 2021, 12

← 1 2 3 4 5 →